Desmethylmisonidazole (Ro 05-9963): clinical pharmacokinetics after multiple oral administration
Journal Article
·
· Int. J. Radiat. Oncol., Biol. Phys.; (United States)
The O-demethylated metabolite of misonidazole, Ro 05-9963, has been administered orally, prior to irradiation, to over 50 patients with malignant disease in order to assess the effectiveness of this compound as a hypoxic cell radiosensitizer. This paper reports the pharmacokinetic data observed in those patients who receive multiple doses to a total of 12 gm/sup -2/. The mean time and magnitude of the peak plasma concentration was determined together with the plasma profile and half-life at the start and finish of each regime of 6, 20, 25 or so fractions. Half-life was independent of drug dose while peak plasma levels rose with increasing amount of drug given. The importance of urinary clearance for this polar drug is indicated by the figure of approximately 50% of administered dose excreted by this route over 24 hours, compared to less than 25% for misonidazole. It was also illustrated by the increased half-life shown by one patient who suffered renal failure during treatment. Peak plasma concentration appeared to be slightly later and were more variable than in the more ideal conditions of the normal volunteer study. In addition, this study confirmed the latter study's findings that absorption is rapid following oral administration of Ro 05-9963, yielding peak plasma levels nearly as high as those seen with misonidazole. Administration in capsules rather than aqueous solution lead to slower absorption, but the peak level did not change.
- Research Organization:
- Mount Vernon Hospital, Northwood, England
- OSTI ID:
- 6720898
- Journal Information:
- Int. J. Radiat. Oncol., Biol. Phys.; (United States), Journal Name: Int. J. Radiat. Oncol., Biol. Phys.; (United States) Vol. 8:3/4; ISSN IOBPD
- Country of Publication:
- United States
- Language:
- English
Similar Records
Clinical experience with nitroimidazoles as radiosensitizers
Clinical testing of Ro-03-8799 - pharmacokinetics, toxicology, tissue and tumor concentrations
Human pharmacokinetics and toxicity of high-dose metronidazole administered orally and intravenously
Journal Article
·
Sun Feb 28 23:00:00 EST 1982
· Int. J. Radiat. Oncol., Biol. Phys.; (United States)
·
OSTI ID:6724310
Clinical testing of Ro-03-8799 - pharmacokinetics, toxicology, tissue and tumor concentrations
Journal Article
·
Sat Sep 01 00:00:00 EDT 1984
· Int. J. Radiat. Oncol., Biol. Phys.; (United States)
·
OSTI ID:6003683
Human pharmacokinetics and toxicity of high-dose metronidazole administered orally and intravenously
Journal Article
·
Fri Dec 31 23:00:00 EST 1982
· Surgery; (United States)
·
OSTI ID:6189337
Related Subjects
560151 -- Radiation Effects on Animals-- Man
560306* -- Chemicals Metabolism & Toxicology-- Man-- (-1987)
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
AZOLES
BIOLOGICAL MATERIALS
BLOOD
BLOOD PLASMA
BODY
BODY FLUIDS
DRUGS
HETEROCYCLIC COMPOUNDS
IMIDAZOLES
KIDNEYS
KINETICS
MATERIALS
ORAL ADMINISTRATION
ORGANIC COMPOUNDS
ORGANIC NITROGEN COMPOUNDS
ORGANS
PATIENTS
PHARMACOLOGY
RADIOSENSITIZERS
560306* -- Chemicals Metabolism & Toxicology-- Man-- (-1987)
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
AZOLES
BIOLOGICAL MATERIALS
BLOOD
BLOOD PLASMA
BODY
BODY FLUIDS
DRUGS
HETEROCYCLIC COMPOUNDS
IMIDAZOLES
KIDNEYS
KINETICS
MATERIALS
ORAL ADMINISTRATION
ORGANIC COMPOUNDS
ORGANIC NITROGEN COMPOUNDS
ORGANS
PATIENTS
PHARMACOLOGY
RADIOSENSITIZERS